Published in Neurobiol Dis on July 03, 2012
Uncovering the role of the insula in non-motor symptoms of Parkinson's disease. Brain (2014) 1.03
Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. Lancet (2014) 1.00
Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions. Hum Brain Mapp (2013) 0.95
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neurosci Biobehav Rev (2014) 0.86
Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Mov Disord (2014) 0.85
Establishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people. J Cereb Blood Flow Metab (2013) 0.84
Medial prefrontal cortex lesions impair decision-making on a rodent gambling task: reversal by D1 receptor antagonist administration. Behav Brain Res (2013) 0.83
Imaging impulse control disorders in Parkinson's disease and their relationship to addiction. J Neural Transm (Vienna) (2012) 0.83
The role of dopamine in risk taking: a specific look at Parkinson's disease and gambling. Front Behav Neurosci (2014) 0.83
Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. Mov Disord (2015) 0.82
Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. J Neurol Neurosurg Psychiatry (2013) 0.82
Impulsive and compulsive behaviors in Parkinson's disease. Annu Rev Clin Psychol (2013) 0.82
Imaging of Dopamine in PD and Implications for Motor and Neuropsychiatric Manifestations of PD. Front Neurol (2013) 0.81
Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol (2016) 0.80
Dopamine receptor mapping with PET imaging in Parkinson's disease. J Neurol (2014) 0.79
Ventral striatal dopamine synthesis capacity predicts financial extravagance in Parkinson's disease. Front Psychol (2013) 0.79
Single versus multiple impulse control disorders in Parkinson's disease: an ¹¹C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. J Neurol (2015) 0.77
Pramipexole-induced disruption of behavioral processes fundamental to intertemporal choice. J Exp Anal Behav (2013) 0.77
Molecular imaging and neural networks in impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord (2015) 0.76
Maladaptive reward-learning and impulse control disorders in patients with Parkinson's disease: a clinical overview and pathophysiology update. J Mov Disord (2014) 0.76
Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors. Pharmacol Biochem Behav (2014) 0.75
Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients. Neuroimage Clin (2016) 0.75
Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. J Neurol Neurosurg Psychiatry (2015) 0.75
Impact of Impulse Control Disorders on Sleep-Wake Regulation in Parkinson's Disease. Parkinsons Dis (2015) 0.75
Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity? Eur J Neurosci (2016) 0.75
Affective disorders in Parkinson's disease. Curr Opin Neurol (2013) 0.75
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc (2005) 27.90
Factor structure of the Barratt impulsiveness scale. J Clin Psychol (1995) 19.86
Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr (1994) 15.38
Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord (2010) 9.34
Simplified reference tissue model for PET receptor studies. Neuroimage (1996) 8.28
MRI-PET registration with automated algorithm. J Comput Assist Tomogr (1993) 5.96
The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol (2004) 5.66
Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci (2011) 4.88
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science (2007) 4.57
Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage (1997) 4.13
Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology (2006) 2.70
Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A (2011) 2.62
L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia (2003) 2.55
Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol (2011) 2.51
Dopaminergic network differences in human impulsivity. Science (2010) 2.49
Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philos Trans R Soc Lond B Biol Sci (2008) 2.40
Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain (2009) 2.35
D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol (2007) 2.28
Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain (2010) 2.11
Roles for nigrostriatal--not just mesocorticolimbic--dopamine in reward and addiction. Trends Neurosci (2009) 2.09
Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron (2010) 1.85
Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology (2010) 1.79
Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology (Berl) (2011) 1.77
Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr (1984) 1.75
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex. J Neurosci (2004) 1.58
Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci U S A (1998) 1.52
Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology (2009) 1.51
The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study. Psychiatry Res (2009) 1.46
Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J (2007) 1.44
The ability of the mesocortical dopamine system to operate in distinct temporal modes. Psychopharmacology (Berl) (2006) 1.42
DAT1 and COMT effects on delay discounting and trait impulsivity in male adolescents with attention deficit/hyperactivity disorder and healthy controls. Neuropsychopharmacology (2010) 1.40
Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task. Proc Natl Acad Sci U S A (2010) 1.25
Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons. Neuroscience (1984) 1.22
Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab (1999) 1.22
Reproducibility of [11 C]FLB 457 binding in extrastriatal regions. Nucl Med Commun (2001) 1.16
Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain (2011) 1.15
The catechol-O-methyl transferase Val158Met polymorphism and experience of reward in the flow of daily life. Neuropsychopharmacology (2007) 1.12
Impulse control disorders in Parkinson's disease: recent advances. Curr Opin Neurol (2011) 1.11
Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology (2008) 1.09
High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol. J Cereb Blood Flow Metab (2009) 1.07
The regulation of dopamine release from nigrostriatal neurons in conscious rats: the role of somatodendritic autoreceptors. Eur J Pharmacol (1991) 1.03
Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11C]FLB 457 PET. J Cereb Blood Flow Metab (2006) 1.02
Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis (2010) 1.01
Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology (2000) 1.00
Topographic organization of ascending dopaminergic projections. Ann N Y Acad Sci (1988) 1.00
Parallel roles for dopamine in pathological gambling and psychostimulant addiction. Curr Drug Abuse Rev (2009) 1.00
A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl) (1997) 0.97
Serotonin and dopamine play complementary roles in gambling to recover losses. Neuropsychopharmacology (2010) 0.93
Dopamine, reward, and frontostriatal circuitry in impulse control disorders in Parkinson's disease: insights from functional imaging. Clin EEG Neurosci (2010) 0.90
Neuroanatomical organization of dopamine neurons in the ventral tegmental area. Ann N Y Acad Sci (1988) 0.88
Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis. Med Hypotheses (2007) 0.88
Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology (2002) 0.86
Parkinson disease: impulsive choice-Parkinson disease and dopaminergic therapy. Nat Rev Neurol (2011) 0.85
Regulation of dopaminergic neuron firing by heterogeneous dopamine autoreceptors in the substantia nigra pars compacta. J Neurochem (2011) 0.83
Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch Neurol (2004) 0.81
Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors. Brain Res (1992) 0.78
6-Hydroxydopamine lesions reduce specific [3H]sulpiride binding in the rat substantia nigra: direct evidence for the existence of nigral D-2 autoreceptors. Eur J Pharmacol (1987) 0.77
Repeated stimulation of dopamine D2-like receptors: reduced responsiveness of nigrostriatal and mesoaccumbens dopamine neurons to quinpirole. J Pharmacol Exp Ther (1995) 0.77
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nat Genet (2013) 2.62
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology (2012) 2.34
Hyperexcitable C nociceptors in fibromyalgia. Ann Neurol (2014) 2.34
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry (2006) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry (2004) 2.04
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry (2004) 2.00
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Functional role of the basal ganglia in the planning and execution of actions. Ann Neurol (2006) 1.96
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Fronto-striatal connections in the human brain: a probabilistic diffusion tractography study. Neurosci Lett (2007) 1.86
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70
Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov Disord (2011) 1.70
An automated method for the extraction of regional data from PET images. Psychiatry Res (2006) 1.67
Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66
Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. J Neurosurg (2011) 1.63
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62
Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J Neurosurg (2002) 1.60
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59
Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol (2008) 1.58
Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol (2013) 1.58
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord (2006) 1.54
Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord (2004) 1.54
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry (2012) 1.54
Consensus paper: combining transcranial stimulation with neuroimaging. Brain Stimul (2009) 1.54
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 1.53
Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Mov Disord (2009) 1.53
18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med (2005) 1.53
Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain (2006) 1.51
Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology (2009) 1.51
Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry (2010) 1.50
Dysfunction of the default mode network in Parkinson disease: a functional magnetic resonance imaging study. Arch Neurol (2009) 1.49
Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci (2012) 1.48